MetaCap

KORU Medical Systems (KRMD) vs Pulmonx (LUNG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pulmonx (LUNG) has outperformed KORU Medical Systems (KRMD) over the past year, gaining 78.5% versus a loss of 33.3%. Over five years, KRMD leads with a -12.6% price change compared with -92.4% for LUNG. KORU Medical Systems is the larger company by market cap ($138.4 million vs $111.9 million), about 1.2 times the size.

KORU Medical Systems converts more of its revenue into profit, with a net margin of -6.4% versus -59.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRMD-33.26%LUNG+78.47%
+128%+41%-47%
Nov 21, 20251 yearNov 20, 2026
KRMD-6.18%LUNG-92.59%
+92%-7%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRMD versus LUNG key metrics
MetricKRMDLUNG
Share price$3.19$2.57
Market cap$138.37M$111.93M
1-day change-7.27%-6.20%
YTD return-45.09%+16.29%
1-year return-33.26%+78.47%
5-year return-12.60%-92.39%
Forward P/E45.57—
EPS (TTM)$-0.02$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.13M$90.50M
Revenue growth (YoY)+22.23%+8.01%
Net income (latest FY)$-2.64M$-54.00M
Gross margin62.26%74.19%
Operating margin-7.23%-59.30%
Net margin-6.41%-59.67%
52-week high$6.61$3.25
52-week low$2.86$1.13
Distance from 52-week high-51.73%-20.92%
Analyst consensusstrong_buynone
Avg. price target upside+92.16%+65.37%
Average volume223.45K641.52K
Shares outstanding43.38M43.55M
Employees73296
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LUNG has outperformed KRMD by 111.7 percentage points over the past year.
  • KORU Medical Systems is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.
  • KORU Medical Systems grew revenue faster in its latest fiscal year (+22.23% vs +8.01%).

About KORU Medical Systems

KRMD stock →

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally.

Health Care · Medical/Dental Instruments · 73 employees

About Pulmonx

LUNG stock →

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Health Care · Medical/Dental Instruments · 296 employees

KRMD vs LUNG FAQ

Which is bigger, KORU Medical Systems or Pulmonx?

KORU Medical Systems (KRMD) is larger, with a market capitalization of $138.37M compared with $111.93M for Pulmonx (LUNG).

Which stock has performed better over the past year, KRMD or LUNG?

LUNG returned +78.47% over the past 12 months, compared with -33.26% for KRMD (price return, excluding dividends). Past performance does not predict future results.

Are KORU Medical Systems and Pulmonx in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons